This pie chart shows research & development funding for STI vaccines and diagnostics by sector — public and philanthropic.
Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.
The Coalition to Accelerate Access to Long-Acting PrEP brings together leading donors, agencies, and advocates aimed at a practical goal: jointly develop strategies and take coordinated action to identify and overcome access challenges to just-approved and future PrEP options. AVAC serves as the Secretariat.
This graphic presents key strategies for advocates to improve vaccine access, highlighting actions like influencing WHO guidelines, community education, addressing intellectual property barriers, and establishing voluntary access mechanisms.
This graphic shows all the steps to cross or overcome in the development of a new product — research & development, intellectual property barriers, registration with regulatory bodies and the implementation of products — along with the important role can advocates play.
This graphic outlines the roles and responsibilities of advocates in vaccine access and production, highlighting six key areas: Advocating for awareness, facilitating regulatory systems, engaging with communities, supporting financial and infrastructure development, adapting to market and community needs, and monitoring commitments to ensure accountability.
Excerpted From the Lab to Jab series.
This graphic highlights the extensive and complex process of vaccine production, encompassing initial design, drug development, large-scale manufacturing, the creation of administration devices, and finally, distribution.
Excerpted From the Lab to Jab series.
mRNA technology is currently being studied for many different uses. Excerpted From the Lab to Jab series.
A detailed graphic showing the biological mechanisms by which mRNA vaccines work. Excerpted From the Lab to Jab series.
As of March 2023, the World Health Organization reported that there are 199 COVID-19 vaccines in pre-clinical development, and 183 in clinical trials. Most are injectable; but 16 candidates are intranasal, 5 are oral, 2 are inhalable, and 1 is an aerosol.
HIV vaccine research is a multifaceted endeavor that requires collaboration across many disciplines to develop a vaccine that protects people from HIV infection. The graphic outlines the different areas of research that are being pursued, including vaccine platforms, immune system research, clinical research capacity, and community engagement.
Excerpted From Lab to Jab.